Congress Presses FDA To Speak Up On OTC/Supplement Combo Products
This article was originally published in The Tan Sheet
Executive Summary
Congressional interest turns up the pressure on FDA to make a statement on Bayer Aspirin with Heart Advantage, and issue a definitive policy on any products that combine dietary supplement and OTC drug ingredients
You may also be interested in...
US FDA Suggests Adding Antioxidants To Drug Formulations To Mitigate Nitrosamine Risks
Agency recommends “mitigation strategies” also including designing formulations that incorporate excipients such as sodium carbonate which modify the micro-environment to neutral or basic pH.
Bayer Reboots Heart Advantage With Promotion For Aspirin
Bayer is using the reformulation of its Bayer Heart Health Advantage cholesterol-lowering phytosterol supplement as an opportunity to cross-promote with its aspirin brand
Bayer Reboots Heart Advantage With Promotion For Aspirin
Bayer is using the reformulation of its Bayer Heart Health Advantage cholesterol-lowering phytosterol supplement as an opportunity to cross-promote with its aspirin brand